Robert Z. Orlowski

Dr. Robert Z. Orlowski is a Professor in the Department of Lymphoma and Myeloma at The University of Texas MD Anderson Cancer Center, where he leads significant research efforts in multiple myeloma and hematologic malignancies. His work focuses on developing novel therapeutic approaches and understanding disease mechanisms to improve patient outcomes.

Dr. Orlowski's research interests span multiple myeloma biology, stem cell transplantation, novel cancer therapeutics, and clinical trial design. His laboratory investigates the molecular mechanisms underlying high-risk myeloma and develops targeted therapies to overcome treatment resistance. He has made substantial contributions to understanding the role of mitochondrial biology, proteomics, and the tumor microenvironment in myeloma progression.

Analysis of Dr. Orlowski's recent publications reveals a strong focus on clinical translation of basic research findings. His work spans from single-cell analysis of myeloma pathobiology to large-scale clinical trials evaluating novel combination therapies. A significant portion of his research addresses treatment optimization for specific patient subgroups, including transplant-ineligible patients, those with high-risk genetic markers like deletion 17p, and patients with CNS involvement.

Dr. Orlowski has been instrumental in advancing treatment paradigms for multiple myeloma through leadership in major clinical trials including MAIA, IMROZ, and GRIFFIN studies. His research has directly contributed to the development of new treatment standards incorporating agents like daratumumab, isatuximab, and pomalidomide.

As a mentor and educator, Dr. Orlowski trains the next generation of hematologic oncologists and researchers, emphasizing both clinical excellence and scientific innovation in the field of plasma cell disorders.